Overview of our Approach
Cancer immunotherapy has revolutionized cancer treatment, led by anti-PD-1/PD-L1 monoclonal antibodies. Furthermore, T cell engagers and bispecific antibodies have gained substantial momentum and relevance as therapeutic option for solid tumor indications over the past years. Yet, despite their success, most patients currently do not benefit from existing drugs, highlighting the need for next-generation cancer immuno-therapies.
The specifics
We are developing next-generation cancer immunotherapies designed to overcome the limitations of current treatments and become future backbone therapies for the most prominent solid tumor indications, by:
Dual-targeting drug candidates expected to show single-agent efficacy in clinical studies, with more than one mode-of action
Drugging targets that are biologically distinguished and orthogonal to the PD-1/PD-L1 axis
Biomarker-driven development – the systematic dissection of the biological target pathways and deep understanding of the mechanism of action of drug candidates enables a specific patient enrichment strategy
Approach
Our approach is shaped by curiosity, focus, and the drive to turn meaningful ideas into real progress.